Drug Trial Radar · NCT06132217
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Jan 30, 2024
Primary completion
Jan 30, 2027
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.
Conditions
- Advanced Solid Tumor
Interventions
SimmitinibDrug
Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
SG001Drug
Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase: Dose Limited Toxicity (DLT)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
- Dose Escalation Phase: Maximum Tolerated Dose (MTD)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
- Dose Escalation Phase: Recommended Phase 2 Dose (RP2D)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)
- Dose Escalation Phase-Incidence rate of Adverse Event (AE).Time frame: From first dose to 30 days post the last dose, with approximately 3 years
- Dose Expansion Phase - Objective Response Rate (ORR) evaluated by Independent Review Committee (IRC) or investigators in advanced solid tumor based on RECIST 1.1.Time frame: Up to approximately 3 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.